Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)—which typically ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

Because the RSV vaccine was ultimately approved for administration during a narrower gestational age window than was ...

A fresh wave of disinformation about vaccines is flaring amid the 2024 campaign. The FDA's top vaccine official believes ...

Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...